Share Name Share Symbol Market Type Share ISIN Share Description
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 3.50 3.00 4.00 3.50 3.50 3.50 0.00 07:46:38
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - -

Collagen Solutions PLC Government Backed Loan and Grant Funding Received

20/05/2020 7:00am

UK Regulatory (RNS & others)

Historical Stock Chart

From May 2020 to Jul 2020

Click Here for more COLLAGEN SOLUTIONS Charts.


RNS Number : 4016N

Collagen Solutions PLC

20 May 2020

20 May 2020

Collagen Solutions plc

("Collagen Solutions" or the "Company")

Government Backed Loan and Grant Funding Received

Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that Collagen Solutions (US) Inc. ("Collagen Solutions USA") and Collagen Solutions (NZ) Limited ("Collagen Solutions NZ"), the Company's wholly owned operating subsidiaries in the USA and New Zealand respectively, have received a mix of loan and grant funding based on those governments' COVID-19 economic support programmes.

Collagen Solutions USA received $US 240,000 in U.S. Government backed loan funding through one of the Company's banking providers. This loan has a two-year term with an interest rate of 1.0% per year, with payments of principal and interest deferred for the first six months. The loan may be forgiven in whole or in part if used for eligible purposes including payroll and rent in the USA in the first eight weeks of the term. The Company believes that a substantial part of this funding will be forgiven, effectively acting as a form of grant. To the extent all or some portion of the principal amount is not forgiven, Collagen Solutions USA is obligated to make equal monthly payments of the remaining principal and interest.

Collagen Solutions NZ also received $NZ 35,000 from the New Zealand Ministry for Social Development's Wage Subsidy Scheme, which does not need to be repaid provided the scheme criteria are met. The Company believes these criteria will be met, and therefore this subsidy is also a form of grant.

The Company continues to pursue additional potential non-dilutive sources of cash including various governments' COVID-19 loans and grants.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 Collagen Solutions Plc 
 Jamal Rushdy, CEO                                                    Via Walbrook 
 Hilary Spence, CFO 
 Cenkos Securities Plc (Nominated 
  Adviser and Broker) 
 Giles Balleny (Corporate Finance)                              Tel: 0207 397 8900 
 Stephen Keys 
 Walbrook PR Ltd                     Tel: 020 7933 8780 or 
 Anna Dunphy                                                    Mob: 07876 741 001 

About Collagen Solutions:

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, tissue engineering, and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic(R). The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.


This announcement (including any information incorporated by reference in this announcement), contains certain statements that are or may be deemed to be forward looking statements. Such statements are prospective in nature. All statements other than historical statements of fact may be forward looking statements. Without limitation, statements containing the words "targets", "plans", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "estimates", "projects", "remain confident that" or "considers" or other similar words may be forward looking statements.

Forward looking statements are based on current expectations that involve or are subject to risks, changes in circumstance, assumptions and uncertainties. Important factors such as business or economic cycles, the measures introduced in response to the COVID-19 pandemic, the terms and conditions of the Company's financing arrangements, tax rates, or increased competition may cause the Company's actual financial results, performance or achievements to differ materially from any forward looking statements. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward looking statements. The information in this announcement is provided only as at the date of its release, and the Company disclaims any obligation to update any forward looking or other statements contained herein, except as required by applicable law.

For more information go to:

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

May 20, 2020 02:00 ET (06:00 GMT)




ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200703 21:01:07